The Oncomine Comprehensive Assay Plus and Oncomine Comprehensive Assay v3 are members of the family of Oncomine assays for clinical cancer research. Oncomine assays are multiple-biomarker next-generation sequencing (NGS)-based assays that have been adopted by leading cancer research institutions around the world and have been used to profile thousands of samples in different translational and clinical research projects including the NCI MATCH trial, delivering consistently reliable results.
Oncomine Comprehensive assays, based on Ion Ampliseq technology and enabled by the Ion Torrent sequencing platforms, provide:
Compare and contrast the Oncomine Comprehensive Assay Plus and the Oncomine Comprehensive Assay v3. Follow the links below to see performance data and learn more about each assay.
|Oncomine Comprehensive Assay Plus||Oncomine Comprehensive Assay v3|
|Summary||Broad, pan-cancer assay for comprehensive genomic profiling of key biomarkers across targeted and immuno-oncology applications||Multi-biomarker assay based on latest clinical oncology research for targeted solid tumor applications|
|Gene count||500+ unique genes||161 unique genes|
|Sample type||FFPE, DNA, and RNA||FFPE, DNA, and RNA|
|Biomarkers||Targeted and immuno-oncology||Targeted|
|Variants||Hotspots, CNVs, fusions, splice variants||Hotspots, CNVs, fusions|
|Platform||Ion GeneStudio S5 Prime System|
Ion GeneStudio S5 Plus System
|Ion Torrent Genexus System|
Ion GeneStudio S5 systems
|Reporting||Yes, with variant data, TMB, MSI status, and relevant insights||Yes, with variant data and relevant insights|
Oncomine Comprehensive assays are part of an end-to-end workflow that includes sample preparation on the Ion Chef System, scalable sequencing with the Ion GeneStudio S5 or Genexus Systems, and post-sequencing analysis on Ion Reporter Software with a results report provided by Oncomine Reporter.
For Research Use Only. Not for use in diagnostic procedures.